Pfizer Inc
PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Aug 4, 2026Score 11/3053% above fair value
$30.52+0.57 (+1.90%)
Close on Oct 30, 2026Market cap $173.95BP/E 40.2Yield 5.64%
Pfizer Zithromax (azithromycin) — U.S. revenues by Quarter
Zithromax (azithromycin) — U.S. revenues ($M) ($M)
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Zithromax (azithromycin) — U.S. revenues ($M) ($M) | Year on year | Source |
|---|
Breakdown
What makes up zithromax (azithromycin) — U.S. revenues
Cite this data
StockData. (2026). Pfizer Zithromax (azithromycin) — U.S. revenues ($M), quarterly [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/zithromax-us
See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.